BUY CHAPTERS

Global Neulasta (Pegfilgrastim) and Biosimilar Market Research Report 2023

Q: How big is the neulasta pegfilgrastim and biosimilar market?

Pegfilgrastim was developed byAmgen.According to QYResearchs new survey global Neulasta Pegfilgrastim and Biosimilar market is projected to reach US 3773.3 million in 2029 increasing from US 2431 million in 2022 with the CAGR of 6.5 during the period of 2023 to 2029.

Q: Who are the key players in the neulasta pegfilgrastim and biosimilar market?

Some of the key players are BRAND, Amgen Inc, Key, Fresenius Kabi, Novartis, Novartis AG, Pfizer Inc, Others.

Code: QYRE-Auto-25R14574

Report

June 2023

Pages:91

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Amneal Pharmaceutical

Neulasta (Pegfilgrastim) and Biosimilar Market Size

According to QYResearch’s new survey, global Neulasta (Pegfilgrastim) and Biosimilar market is projected to reach US$ 3773.3 million in 2029, increasing from US$ 2431 million in 2022, with the CAGR of 6.5% during the period of 2023 to 2029.

Neulasta (Pegfilgrastim) and Biosimilar Market

Pegfilgrastim, sold under the brand name Neulasta among others, is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim.It serves to stimulate the production of white blood cells (neutrophils). Pegfilgrastim was developed by Amgen.

Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Neulasta (Pegfilgrastim) and Biosimilar market research.

Key manufacturers engaged in the Neulasta (Pegfilgrastim) and Biosimilar industry include Amgen, Viatris, Coherus, Novartis, Pfizer, Amneal Pharmaceutical and Fresenius Kabi, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % volume of Neulasta (Pegfilgrastim) and Biosimilar were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Neulasta (Pegfilgrastim) and Biosimilar market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Neulasta (Pegfilgrastim) and Biosimilar market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Scope of Neulasta (Pegfilgrastim) and Biosimilar Market Report

Report Metric	Details
Report Name	Neulasta (Pegfilgrastim) and Biosimilar Market
Accounted market size in 2022	US$ 2431 million
Forecasted market size in 2029	US$ 3773.3 million
CAGR	6.5%
Base Year	2022
Forecasted years	2023 - 2029
Segment by Type	Brand Biosimilar
Segment by Application	Hospital Pharmacy Other
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Amgen, Viatris, Coherus, Novartis, Pfizer, Amneal Pharmaceutical, Fresenius Kabi
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

FAQ for this report

How fast is Neulasta (Pegfilgrastim) and Biosimilar Market market growing?

Ans: The Neulasta (Pegfilgrastim) and Biosimilar Market market witnessing a CAGR of 6.5% during the forecast period 2023-2029.

What is the Neulasta (Pegfilgrastim) and Biosimilar Market market size in 2029?

Ans: According to QYResearch’s new survey, global Neulasta (Pegfilgrastim) and Biosimilar market is projected to reach US$ 3773.3 million in 2029, increasing from US$ 2431 million in 2022, with the CAGR of 6.5% during the period of 2023 to 2029.

1 Neulasta (Pegfilgrastim) and Biosimilar Market Overview

1.1 Product Overview and Scope of Neulasta (Pegfilgrastim) and Biosimilar

1.2 Neulasta (Pegfilgrastim) and Biosimilar Segment by Type

1.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Value Comparison by Type (2023-2029)

1.2.2 Brand

1.2.3 Biosimilar

1.3 Neulasta (Pegfilgrastim) and Biosimilar Segment by Application

1.3.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Value by Application: (2023-2029)

1.3.2 Hospital

1.3.3 Pharmacy

1.3.4 Other

1.4 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size Estimates and Forecasts

1.4.1 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue 2018-2029

1.4.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales 2018-2029

1.4.3 Global Neulasta (Pegfilgrastim) and Biosimilar Market Average Price (2018-2029)

1.5 Assumptions and Limitations

2 Neulasta (Pegfilgrastim) and Biosimilar Market Competition by Manufacturers

2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Manufacturers (2018-2023)

2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Manufacturers (2018-2023)

2.3 Global Neulasta (Pegfilgrastim) and Biosimilar Average Price by Manufacturers (2018-2023)

2.4 Global Neulasta (Pegfilgrastim) and Biosimilar Industry Ranking 2021 VS 2022 VS 2023

2.5 Global Key Manufacturers of Neulasta (Pegfilgrastim) and Biosimilar, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Neulasta (Pegfilgrastim) and Biosimilar, Product Type & Application

2.7 Neulasta (Pegfilgrastim) and Biosimilar Market Competitive Situation and Trends

2.7.1 Neulasta (Pegfilgrastim) and Biosimilar Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Neulasta (Pegfilgrastim) and Biosimilar Players Market Share by Revenue

2.7.3 Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Neulasta (Pegfilgrastim) and Biosimilar Retrospective Market Scenario by Region

3.1 Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region: 2018 Versus 2022 Versus 2029

3.2 Global Neulasta (Pegfilgrastim) and Biosimilar Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region: 2018-2029

3.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region: 2018-2023

3.2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region: 2024-2029

3.3 Global Neulasta (Pegfilgrastim) and Biosimilar Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region: 2018-2029

3.3.1 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region: 2018-2023

3.3.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region: 2024-2029

3.4 North America Neulasta (Pegfilgrastim) and Biosimilar Market Facts & Figures by Country

3.4.1 North America Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029

3.4.2 North America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2018-2029)

3.4.3 North America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2018-2029)

3.4.4 United States

3.4.5 Canada

3.5 Europe Neulasta (Pegfilgrastim) and Biosimilar Market Facts & Figures by Country

3.5.1 Europe Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029

3.5.2 Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2018-2029)

3.5.3 Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2018-2029)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Market Facts & Figures by Country

3.6.1 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029

3.6.2 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2018-2029)

3.6.3 Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2018-2029)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Neulasta (Pegfilgrastim) and Biosimilar Market Facts & Figures by Country

3.7.1 Latin America Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029

3.7.2 Latin America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2018-2029)

3.7.3 Latin America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2018-2029)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Market Facts & Figures by Country

3.8.1 Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029

3.8.2 Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2018-2029)

3.8.3 Middle East and Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2018-2029)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2018-2029)

4.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2018-2023)

4.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Type (2024-2029)

4.1.3 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2018-2029)

4.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Type (2018-2029)

4.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Type (2018-2023)

4.2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Type (2024-2029)

4.2.3 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Type (2018-2029)

4.3 Global Neulasta (Pegfilgrastim) and Biosimilar Price by Type (2018-2029)

5 Segment by Application

5.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2018-2029)

5.1.1 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2018-2023)

5.1.2 Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Application (2024-2029)

5.1.3 Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2018-2029)

5.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Application (2018-2029)

5.2.1 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Application (2018-2023)

5.2.2 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Application (2024-2029)

5.2.3 Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Application (2018-2029)

5.3 Global Neulasta (Pegfilgrastim) and Biosimilar Price by Application (2018-2029)

6 Key Companies Profiled

6.1 Amgen

6.1.1 Amgen Corporation Information

6.1.2 Amgen Description and Business Overview

6.1.3 Amgen Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.1.4 Amgen Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio

6.1.5 Amgen Recent Developments/Updates

6.2 Viatris

6.2.1 Viatris Corporation Information

6.2.2 Viatris Description and Business Overview

6.2.3 Viatris Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.2.4 Viatris Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio

6.2.5 Viatris Recent Developments/Updates

6.3 Coherus

6.3.1 Coherus Corporation Information

6.3.2 Coherus Description and Business Overview

6.3.3 Coherus Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.3.4 Coherus Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio

6.3.5 Coherus Recent Developments/Updates

6.4 Novartis

6.4.1 Novartis Corporation Information

6.4.2 Novartis Description and Business Overview

6.4.3 Novartis Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.4.4 Novartis Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio

6.4.5 Novartis Recent Developments/Updates

6.5 Pfizer

6.5.1 Pfizer Corporation Information

6.5.2 Pfizer Description and Business Overview

6.5.3 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.5.4 Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio

6.5.5 Pfizer Recent Developments/Updates

6.6 Amneal Pharmaceutical

6.6.1 Amneal Pharmaceutical Corporation Information

6.6.2 Amneal Pharmaceutical Description and Business Overview

6.6.3 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.6.4 Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio

6.6.5 Amneal Pharmaceutical Recent Developments/Updates

6.7 Fresenius Kabi

6.6.1 Fresenius Kabi Corporation Information

6.6.2 Fresenius Kabi Description and Business Overview

6.6.3 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.4.4 Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product Portfolio

6.7.5 Fresenius Kabi Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Neulasta (Pegfilgrastim) and Biosimilar Industry Chain Analysis

7.2 Neulasta (Pegfilgrastim) and Biosimilar Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Neulasta (Pegfilgrastim) and Biosimilar Production Mode & Process

7.4 Neulasta (Pegfilgrastim) and Biosimilar Sales and Marketing

7.4.1 Neulasta (Pegfilgrastim) and Biosimilar Sales Channels

7.4.2 Neulasta (Pegfilgrastim) and Biosimilar Distributors

7.5 Neulasta (Pegfilgrastim) and Biosimilar Customers

8 Neulasta (Pegfilgrastim) and Biosimilar Market Dynamics

8.1 Neulasta (Pegfilgrastim) and Biosimilar Industry Trends

8.2 Neulasta (Pegfilgrastim) and Biosimilar Market Drivers

8.3 Neulasta (Pegfilgrastim) and Biosimilar Market Challenges

8.4 Neulasta (Pegfilgrastim) and Biosimilar Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Amneal Pharmaceutical

List of Tables

Table 1. Global Neulasta (Pegfilgrastim) and Biosimilar Market Value Comparison by Type (2023-2029) & (US$ Million)

Table 2. Global Neulasta (Pegfilgrastim) and Biosimilar Market Value Comparison by Application (2023-2029) & (US$ Million)

Table 3. Global Neulasta (Pegfilgrastim) and Biosimilar Market Competitive Situation by Manufacturers in 2022

Table 4. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units) of Key Manufacturers (2018-2023)

Table 5. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Manufacturers (2018-2023)

Table 6. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue (US$ Million) by Manufacturers (2018-2023)

Table 7. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Share by Manufacturers (2018-2023)

Table 8. Global Market Neulasta (Pegfilgrastim) and Biosimilar Average Price (US$/Unit) of Key Manufacturers (2018-2023)

Table 9. Global Key Players of Neulasta (Pegfilgrastim) and Biosimilar, Industry Ranking, 2021 VS 2022 VS 2023

Table 10. Global Key Manufacturers of Neulasta (Pegfilgrastim) and Biosimilar, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Neulasta (Pegfilgrastim) and Biosimilar, Product Type & Application

Table 12. Global Key Manufacturers of Neulasta (Pegfilgrastim) and Biosimilar, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Neulasta (Pegfilgrastim) and Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neulasta (Pegfilgrastim) and Biosimilar as of 2022)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

Table 17. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2018-2023) & (K Units)

Table 18. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region (2018-2023)

Table 19. Global Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2024-2029) & (K Units)

Table 20. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region (2024-2029)

Table 21. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region (2018-2023) & (US$ Million)

Table 22. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Region (2018-2023)

Table 23. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region (2024-2029) & (US$ Million)

Table 24. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Region (2024-2029)

Table 25. North America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

Table 26. North America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2018-2023) & (K Units)

Table 27. North America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2024-2029) & (K Units)

Table 28. North America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)

Table 29. North America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2024-2029) & (US$ Million)

Table 30. Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

Table 31. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2018-2023) & (K Units)

Table 32. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2024-2029) & (K Units)

Table 33. Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)

Table 34. Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2024-2029) & (US$ Million)

Table 35. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)

Table 36. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2018-2023) & (K Units)

Table 37. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales by Region (2024-2029) & (K Units)

Table 38. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region (2018-2023) & (US$ Million)

Table 39. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Revenue by Region (2024-2029) & (US$ Million)

Table 40. Latin America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

Table 41. Latin America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2018-2023) & (K Units)

Table 42. Latin America Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2024-2029) & (K Units)

Table 43. Latin America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)

Table 44. Latin America Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2024-2029) & (US$ Million)

Table 45. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

Table 46. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2018-2023) & (K Units)

Table 47. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales by Country (2024-2029) & (K Units)

Table 48. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)

Table 49. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue by Country (2024-2029) & (US$ Million)

Table 50. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units) by Type (2018-2023)

Table 51. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units) by Type (2024-2029)

Table 52. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2018-2023)

Table 53. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Type (2024-2029)

Table 54. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue (US$ Million) by Type (2018-2023)

Table 55. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue (US$ Million) by Type (2024-2029)

Table 56. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Type (2018-2023)

Table 57. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Type (2024-2029)

Table 58. Global Neulasta (Pegfilgrastim) and Biosimilar Price (US$/Unit) by Type (2018-2023)

Table 59. Global Neulasta (Pegfilgrastim) and Biosimilar Price (US$/Unit) by Type (2024-2029)

Table 60. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units) by Application (2018-2023)

Table 61. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units) by Application (2024-2029)

Table 62. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2018-2023)

Table 63. Global Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Application (2024-2029)

Table 64. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue (US$ Million) by Application (2018-2023)

Table 65. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue (US$ Million) by Application (2024-2029)

Table 66. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Application (2018-2023)

Table 67. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Application (2024-2029)

Table 68. Global Neulasta (Pegfilgrastim) and Biosimilar Price (US$/Unit) by Application (2018-2023)

Table 69. Global Neulasta (Pegfilgrastim) and Biosimilar Price (US$/Unit) by Application (2024-2029)

Table 70. Amgen Corporation Information

Table 71. Amgen Description and Business Overview

Table 72. Amgen Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

Table 73. Amgen Neulasta (Pegfilgrastim) and Biosimilar Product

Table 74. Amgen Recent Developments/Updates

Table 75. Viatris Corporation Information

Table 76. Viatris Description and Business Overview

Table 77. Viatris Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

Table 78. Viatris Neulasta (Pegfilgrastim) and Biosimilar Product

Table 79. Viatris Recent Developments/Updates

Table 80. Coherus Corporation Information

Table 81. Coherus Description and Business Overview

Table 82. Coherus Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

Table 83. Coherus Neulasta (Pegfilgrastim) and Biosimilar Product

Table 84. Coherus Recent Developments/Updates

Table 85. Novartis Corporation Information

Table 86. Novartis Description and Business Overview

Table 87. Novartis Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

Table 88. Novartis Neulasta (Pegfilgrastim) and Biosimilar Product

Table 89. Novartis Recent Developments/Updates

Table 90. Pfizer Corporation Information

Table 91. Pfizer Description and Business Overview

Table 92. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

Table 93. Pfizer Neulasta (Pegfilgrastim) and Biosimilar Product

Table 94. Pfizer Recent Developments/Updates

Table 95. Amneal Pharmaceutical Corporation Information

Table 96. Amneal Pharmaceutical Description and Business Overview

Table 97. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

Table 98. Amneal Pharmaceutical Neulasta (Pegfilgrastim) and Biosimilar Product

Table 99. Amneal Pharmaceutical Recent Developments/Updates

Table 100. Fresenius Kabi Corporation Information

Table 101. Fresenius Kabi Description and Business Overview

Table 102. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

Table 103. Fresenius Kabi Neulasta (Pegfilgrastim) and Biosimilar Product

Table 104. Fresenius Kabi Recent Developments/Updates

Table 105. Key Raw Materials Lists

Table 106. Raw Materials Key Suppliers Lists

Table 107. Neulasta (Pegfilgrastim) and Biosimilar Distributors List

Table 108. Neulasta (Pegfilgrastim) and Biosimilar Customers List

Table 109. Neulasta (Pegfilgrastim) and Biosimilar Market Trends

Table 110. Neulasta (Pegfilgrastim) and Biosimilar Market Drivers

Table 111. Neulasta (Pegfilgrastim) and Biosimilar Market Challenges

Table 112. Neulasta (Pegfilgrastim) and Biosimilar Market Restraints

Table 113. Research Programs/Design for This Report

Table 114. Key Data Information from Secondary Sources

Table 115. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Neulasta (Pegfilgrastim) and Biosimilar

Figure 2. Global Neulasta (Pegfilgrastim) and Biosimilar Market Value Comparison by Type (2023-2029) & (US$ Million)

Figure 3. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Type in 2022 & 2029

Figure 4. Brand Product Picture

Figure 5. Biosimilar Product Picture

Figure 6. Global Neulasta (Pegfilgrastim) and Biosimilar Market Value Comparison by Application (2023-2029) & (US$ Million)

Figure 7. Global Neulasta (Pegfilgrastim) and Biosimilar Market Share by Application in 2022 & 2029

Figure 8. Hospital

Figure 9. Pharmacy

Figure 10. Other

Figure 11. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue, (US$ Million), 2018 VS 2022 VS 2029

Figure 12. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size (2018-2029) & (US$ Million)

Figure 13. Global Neulasta (Pegfilgrastim) and Biosimilar Sales (2018-2029) & (K Units)

Figure 14. Global Neulasta (Pegfilgrastim) and Biosimilar Average Price (US$/Unit) & (2018-2029)

Figure 15. Neulasta (Pegfilgrastim) and Biosimilar Report Years Considered

Figure 16. Neulasta (Pegfilgrastim) and Biosimilar Sales Share by Manufacturers in 2022

Figure 17. Global Neulasta (Pegfilgrastim) and Biosimilar Revenue Share by Manufacturers in 2022

Figure 18. The Global 5 and 10 Largest Neulasta (Pegfilgrastim) and Biosimilar Players: Market Share by Revenue in 2022

Figure 19. Neulasta (Pegfilgrastim) and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022

Figure 20. Global Neulasta (Pegfilgrastim) and Biosimilar Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

Figure 21. North America Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country (2018-2029)

Figure 22. North America Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Country (2018-2029)

Figure 23. United States Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

Figure 24. Canada Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

Figure 25. Europe Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country (2018-2029)

Figure 26. Europe Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Country (2018-2029)

Figure 27. Germany Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

Figure 28. France Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

Figure 29. U.K. Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

Figure 30. Italy Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

Figure 31. Russia Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

Figure 32. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Region (2018-2029)

Figure 33. Asia Pacific Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Region (2018-2029)

Figure 34. China Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

Figure 35. Japan Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

Figure 36. South Korea Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

Figure 37. India Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

Figure 38. Australia Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

Figure 39. China Taiwan Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

Figure 40. Southeast Asia Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

Figure 41. Latin America Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country (2018-2029)

Figure 42. Latin America Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Country (2018-2029)

Figure 43. Mexico Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

Figure 44. Brazil Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

Figure 45. Argentina Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

Figure 46. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Sales Market Share by Country (2018-2029)

Figure 47. Middle East & Africa Neulasta (Pegfilgrastim) and Biosimilar Revenue Market Share by Country (2018-2029)

Figure 48. Turkey Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

Figure 49. Saudi Arabia Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

Figure 50. UAE Neulasta (Pegfilgrastim) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

Figure 51. Global Sales Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Type (2018-2029)

Figure 52. Global Revenue Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Type (2018-2029)

Figure 53. Global Neulasta (Pegfilgrastim) and Biosimilar Price (US$/Unit) by Type (2018-2029)

Figure 54. Global Sales Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Application (2018-2029)

Figure 55. Global Revenue Market Share of Neulasta (Pegfilgrastim) and Biosimilar by Application (2018-2029)

Figure 56. Global Neulasta (Pegfilgrastim) and Biosimilar Price (US$/Unit) by Application (2018-2029)

Figure 57. Neulasta (Pegfilgrastim) and Biosimilar Value Chain

Figure 58. Neulasta (Pegfilgrastim) and Biosimilar Production Process

Figure 59. Channels of Distribution (Direct Vs Distribution)

Figure 60. Distributors Profiles

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

Global Neulasta (Pegfilgrastim) and Biosimilar Market Research Report 2023

Published Date: June 2023

Report Code: QYRE-Auto-25R14574

Global Neulasta (Pegfilgrastim) and Biosimilar Market Research Report 2023

FEATURED COMPANIES

Neulasta (Pegfilgrastim) and Biosimilar Market Size

Neulasta (Pegfilgrastim) and Biosimilar Market

Report Scope

Scope of Neulasta (Pegfilgrastim) and Biosimilar Market Report

FAQ for this report

How fast is Neulasta (Pegfilgrastim) and Biosimilar Market market growing?

What is the Neulasta (Pegfilgrastim) and Biosimilar Market market size in 2029?

FEATURED COMPANIES

RELATED REPORTS